Global Chronic Lymphocytic Leukemia Therapeutics Market 2015-2019

慢性リンパ性白血病(CLL)治療薬の世界市場2015-2019

◆タイトル:Global Chronic Lymphocytic Leukemia Therapeutics Market 2015-2019
◆商品コード:IRTNTR6598
◆調査・発行会社:Technavio (Infiniti Research Ltd.)
◆発行日:2015年8月5日
◆ページ数:87
◆資料形式:pdf / 英語
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD2,500 ⇒換算¥275,000見積依頼/購入/質問フォーム
Five UserUSD3,000 ⇒換算¥330,000見積依頼/購入/質問フォーム
Enterprise License(全社内共有可)USD4,000 ⇒換算¥440,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、資料に記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はTechnavio (Infiniti Research Ltd.)の日本における正規販売代理店です。

【資料の概要】

当調査レポートでは、慢性リンパ性白血病(CLL)治療薬の世界市場について調査・分析し、エグゼクティブサマリー、市場概観、業界の構造分析、慢性リンパ性白血病(CLL)治療薬の世界市場規模及び予測、種類別分析、投与経路(ROA)別分析、市場シェア、地域別分析、購買基準、市場成長要因、市場の課題、市場動向、競争状況、主要企業(ベンダー)分析などの情報をお届けいたします。

About Chronic Lymphocytic Leukemia
Chronic lymphocytic leukemia is a malignant condition characterized by increased production of lymphocytes. It has been observed that the cancer first affects B-lymphocytes and then it can spread to other parts of the body. This leukemia is diagnosed mostly at later stages because of the slow buildup of the cancerous cells. During the course of the disease, the malignancy spreads to the spleen, liver, and lymph nodes. The course of the disease is heterogeneous, and prognosis is difficult. Symptoms include swelling of the lymph nodes, fatigue, fever, infection, pain beneath the ribs, and weight loss. Chronic lymphocytic leukemia can be treated with radiation, steroids, chemotherapy, targeted therapy, transplants (bone marrow, stem cell), and surgical procedure to remove the spleen (splenectomy).

Technavio’s analysts forecast the global chronic lymphocytic leukemia therapeutics market to grow at a CAGR of 18.52% over the period 2014-2019.

[Covered in this Report]
In this report, Technavio covers the present scenario and growth prospects of the global chronic lymphocytic leukemia therapeutics market for the period 2015-2019. To calculate the market size, we consider revenue generated from the sales of various drugs used in the treatment of chronic lymphocytic leukemia.

Based on the type of molecule, we group the market into two categories:
• Biologics
• Small molecules

Based on the route of administration, we group the market into two:
• Oral
• Parenteral

This report includes a discussion of the market in the following three regions:
• Americas: The major countries focused in the Americas are the US, Canada, Mexico, and Brazil
• EMEA: The major countries in this region are the UK, Germany, Italy, France, Spain and Middle

Eastern and African countries such as Israel, South Africa, Egypt, Sudan, Kuwait, Saudi Arabia, Qatar, and the UAE

• APAC: The major countries in this region are Japan, China, Australia, Singapore, South Korea, and India. APAC is a major untapped market with many leading vendors in the global chronic lymphocytic leukemia therapeutics market.

The report also presents the vendor landscape and a corresponding detailed analysis of the top vendors in the market. In addition, it discusses the major drivers and challenges, as well as the key trends.

[Key Regions]
• Americas
• APAC
• EMEA

[Key Vendors]
• F. Hoffmann-La Roche
• Novartis
• Teva Pharmaceutical Industries

[Other Prominent Vendors]
• Actavis
• Amgen
• Aryogen
• Astellas
• Bristol-Myers Squibb
• Eagle Pharmaceuticals
• Eisai
• Fresenius Kabi
• Genmab
• Gilead Sciences
• H. Lundbeck
• Hospira
• idd biotech
• Immunomedics
• Johnson & Johnson
• Mundipharma
• Mylan
• Noxxon
• Ono Pharmaceutical
• PDL BioPharma
• Pfizer
• Pharmacyclics
• Regeneron
• Sagent Pharmaceutical
• Sanofi
• SymBio Pharmaceuticals
• TheraMAB

[Market Driver]
• Increase in Patient Pool
• For a full, detailed list, view our report

[Market Challenge]
• Unknown Disease Etiology
• For a full, detailed list, view our report

[Market Trend]
• Strategic Alliances
• For a full, detailed list, view our report

[Key Questions Answered in this Report]
• What will the market size be in 2019 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

【資料の目次】

01. Executive Summary

02.List of Abbreviations

03.Scope of the Report
03.1 Market Overview
03.2 Product Offerings

04.Product Profiles
04.1.1 Gazyva/Gazyvaro
04.1.2 MabThera/Rituxan
04.1.3 Arzerra
04.1.4 Treanda

05.Market Research Methodology
05.1 Market Research Process
05.2 Research Methodology

06.Disease Overview
06.1 Understanding the Disease
06.2 Types of Chronic Lymphocytic Leukemia
06.3 Symptoms
06.4 Diagnosis
06.5 Staging
06.6 Epidemiology
06.7 Management
06.8 Economic Burden

07.Introduction

08.Market Landscape
08.1 Market Overview
08.2 Market Size and Forecast
08.3 Five Forces Analysis

09.Pipeline Portfolio
09.1 Key Information on the Major Pipeline Molecules
09.1.1 RG 105 SC Formulation
09.1.2 Obinutuzumab/ Venetoclax
09.1.3 RG 7596 (Polatuzumab vedotin)
09.1.4 RG 7601 (Venetoclax)

10.Market Segmentation by Route of Administration
10.1 Oral
10.2 Parenteral

11.Market Segmentation by Type of Molecule
11.1 Small Molecules
11.2 Biologics

12.Geographical Segmentation

13.Buying Criteria

14.Market Growth Drivers

15.Drivers and their Impact

16.Market Challenges

17.Impact of Drivers and Challenges

18.Market Trends

19.Trends and their Impact

20.Vendor Landscape
20.1 Competitive Scenario
20.1.1 Key News
20.1.2 Mergers and Acquisitions
20.2 Market Share Analysis 2014
20.2.1 F. Hoffmann-La Roche
20.2.2 Teva Pharmaceutical Industries
20.2.3 Novartis
20.3 Other and Future Prominent Vendors

21.Key Vendor Analysis
21.1 F. Hoffmann-La Roche
21.1.1 Key Facts
21.1.2 Business Overview
21.1.3 Business Segmentation
21.1.4 Business Segmentation by Revenue 2012 and 2013
21.1.5 Sales by Geography
21.1.6 Business Strategy
21.1.7 Key Information
21.1.8 SWOT Analysis
21.2 Novartis
21.2.1 Key Facts
21.2.2 Business Description
21.2.3 Business Segmentation
21.2.4 Revenue by Business Segmentation
21.2.5 Revenue Comparison 2012 and 2013
21.2.6 Sales by Geography
21.2.7 Business Strategy
21.2.8 Key Developments
21.2.9 SWOT Analysis
21.3 Teva Pharmaceutical Industries
21.3.1 Key Facts
21.3.2 Business Overview
21.3.3 Business Segmentation
21.3.4 Revenue by Business Segmentation
21.3.5 Revenue Comparison 2012 and 2013
21.3.6 Revenue Segmentation by Geography
21.3.7 Business Strategy
21.3.8 Key Developments
21.3.9 SWOT Analysis

22.Other Reports in this Series

[List of Exhibits]

Exhibit 1: Market Research Methodology
Exhibit 2: Snapshot of Chronic Lymphocytic Leukemia
Exhibit 3: Type of Chronic Lymphocytic Leukemia
Exhibit 4: Major Diagnostic Procedures to Determine Chronic Lymphocytic Leukemia
Exhibit 5: Other Diagnostic Procedures to Determine Chronic Lymphocytic Leukemia
Exhibit 6: Rai Staging of Chronic Lymphocytic Leukemia
Exhibit 7: Binet Staging of Chronic Lymphocytic Leukemia
Exhibit 8: Management of Chronic Lymphocytic Leukemia
Exhibit 9: Economic Burden of Chronic Lymphocytic Leukemia
Exhibit 10: Global Chronic Lymphocytic Leukemia Therapeutics Market 2014-2019 ($ millions)
Exhibit 11: Key Takeaways: Global Chronic Lymphocytic Leukemia Therapeutics Market
Exhibit 12: Drug Candidates by Stage of Development, in percentage
Exhibit 13: Segmentation of Global Chronic Lymphocytic Leukemia Therapeutics Market by Route of Administration
Exhibit 14: Segmentation of Global Chronic Lymphocytic Leukemia Therapeutics Market by Type of Molecules
Exhibit 15: Segmentation of Global Chronic Lymphocytic Leukemia Therapeutics Market by Geography, 2014
Exhibit 16: Drivers of Global Chronic Lymphocytic Leukemia Therapeutics Market
Exhibit 17: Challenges of Global Chronic Lymphocytic Leukemia Therapeutics Market
Exhibit 18: Trends of Global Chronic Lymphocytic Leukemia Therapeutics Market
Exhibit 19: Global Sales and YoY Growth Rate of Rituxan/MabThera 2010-2014 ($ millions)
Exhibit 20: Global Sales and YoY Growth Rate of Treanda 2010-2014 ($ millions)
Exhibit 21: Global Sales and YoY Growth Rate of Arzerra 2010-2014($ millions)
Exhibit 22: Sales and YoY Growth Rate of Arzerra in US 2010-2014 ($ millions)
Exhibit 23: Sales and YoY Growth Rate of Arzerra in Europe 2010-2014 ($ millions)
Exhibit 24: Region-wise Revenue Comparison of Arzerra 2010-2014 ($ millions)
Exhibit 25: Business Segmentation of F. Hoffmann-La Roche Ltd. 2013
Exhibit 26: F. Hoffmann-La Roche Ltd.: Business Segmentation by Revenue 2012 and 2013
Exhibit 27: F. Hoffmann-La Roche Ltd.: Sales by Geography 2013 (Pharmaceuticals Division)
Exhibit 28: F. Hoffmann-La Roche Ltd.: Sales by Geography 2013 (Diagnostics Division)
Exhibit 29: Novartis AG: Business Segmentation
Exhibit 30: Novartis AG: Revenue by Business Segmentation 2013
Exhibit 31: Novartis AG: Revenue by Business Segmentation 2012 and 2013 ($ millions)
Exhibit 32: Novartis AG: Revenue by Geographical Segmentation 2013
Exhibit 33: Teva Pharmaceutical Industries Ltd.: Business Segmentation
Exhibit 34: Teva Pharmaceutical Industries Ltd.: Revenue by Business Segmentation 2013
Exhibit 35: Teva Pharmaceutical Industries Ltd.: Revenue by Business Segmentation 2012 and 2013 ($ millions)
Exhibit 36: Teva Pharmaceutical Industries Ltd.: Revenue by Geographical Segmentation 2013



【掲載企業】

F. Hoffmann-La Roche, Novartis and Teva Pharmaceutical Industries, Actavis, Amgen, Aryogen, Astellas, Bristol-Myers Squibb, Eagle Pharmaceuticals, Eisai, Fresenius Kabi, Genmab, Gilead Sciences, H. Lundbeck, Hospira, idd biotech, Immunomedics, Johnson & Johnson, Mundipharma, Mylan, Noxxon, Ono Pharmaceutical

【資料のキーワード】

慢性リンパ性白血病(CLL)治療薬、白血病、治療、医薬品、パイプライン

【調査方法】

一次資料による調査(業界専門家、ベンダー、代理店、顧客等を対象にしたデプスインタビュー調査など)及び二次資料による調査(Technavio独自のプラットフォーム、産業書籍、企業報告書、ニュース記事、アナリストレポート、貿易協会、政府機関発行データなど)

★調査レポート[慢性リンパ性白血病(CLL)治療薬の世界市場2015-2019] (Global Chronic Lymphocytic Leukemia Therapeutics Market 2015-2019 / IRTNTR6598)販売に関する免責事項
[慢性リンパ性白血病(CLL)治療薬の世界市場2015-2019] (Global Chronic Lymphocytic Leukemia Therapeutics Market 2015-2019 / IRTNTR6598)についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆